WO2001085782A3 - Fusion receptor from TNF family - Google Patents

Fusion receptor from TNF family Download PDF

Info

Publication number
WO2001085782A3
WO2001085782A3 PCT/US2001/004568 US0104568W WO0185782A3 WO 2001085782 A3 WO2001085782 A3 WO 2001085782A3 US 0104568 W US0104568 W US 0104568W WO 0185782 A3 WO0185782 A3 WO 0185782A3
Authority
WO
WIPO (PCT)
Prior art keywords
agp
proteins
cells
domain
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/004568
Other languages
French (fr)
Other versions
WO2001085782A2 (en
Inventor
William J Boyle
Hailing Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to MXPA02007574A priority Critical patent/MXPA02007574A/en
Priority to JP2001582381A priority patent/JP2003532406A/en
Priority to AU36958/01A priority patent/AU3695801A/en
Priority to CA002400214A priority patent/CA2400214A1/en
Priority to EP01909174A priority patent/EP1254227A2/en
Publication of WO2001085782A2 publication Critical patent/WO2001085782A2/en
Publication of WO2001085782A3 publication Critical patent/WO2001085782A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A member of the tumor necrosis factor family and its receptor are described. This member is primarily expressed in B cells and its expression correlates to increases in the number of B cells and immunoglobulins produced. The natural, preferred human ortholog is here called AGP-3R. The protein is a type III transmembrane protein and has an amino terminal extracellular domain, a transmembrane domain, and a carboxy terminal intracellular domain. AGP-3R-related proteins of the invention may be membrane-associated or in soluble form, recombinantly produced or isolated after natural production. The invention provides for nucleic acids encoding such AGP-3R-related proteins, vectors and host cells expressing the polypeptides, and methods for producing recombinant proteins. Antibodies or fragments thereof that specifically bind the proteins are also provided.
PCT/US2001/004568 2000-02-11 2001-02-12 Fusion receptor from tnf family Ceased WO2001085782A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA02007574A MXPA02007574A (en) 2000-02-11 2001-02-12 Receptor from tnf family.
JP2001582381A JP2003532406A (en) 2000-02-11 2001-02-12 Fusion receptor derived from TNF family
AU36958/01A AU3695801A (en) 2000-02-11 2001-02-12 Receptor from tnf family
CA002400214A CA2400214A1 (en) 2000-02-11 2001-02-12 Fusion receptor from tnf family
EP01909174A EP1254227A2 (en) 2000-02-11 2001-02-12 Fusion receptor from tnf family

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18180000P 2000-02-11 2000-02-11
US60/181,800 2000-02-11

Publications (2)

Publication Number Publication Date
WO2001085782A2 WO2001085782A2 (en) 2001-11-15
WO2001085782A3 true WO2001085782A3 (en) 2002-04-25

Family

ID=22665864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004568 Ceased WO2001085782A2 (en) 2000-02-11 2001-02-12 Fusion receptor from tnf family

Country Status (6)

Country Link
US (1) US20020160416A1 (en)
EP (1) EP1254227A2 (en)
AU (1) AU3695801A (en)
CA (1) CA2400214A1 (en)
MX (1) MXPA02007574A (en)
WO (1) WO2001085782A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
HU229910B1 (en) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks Peptides and related molecules that bind to tall-1
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
ES2537738T3 (en) 2003-06-05 2015-06-11 Genentech, Inc. Combination therapy for B cell disorders
WO2005075511A1 (en) 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
DK2233149T3 (en) 2007-10-16 2016-05-17 Zymogenetics Inc COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
EP2507267B1 (en) 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
AU2012211725A1 (en) 2011-02-02 2013-08-29 Daiichi Sankyo Company, Limited Peptide library
KR101963914B1 (en) 2011-02-23 2019-03-29 매사추세츠 인스티튜트 오브 테크놀로지 Water soluble membrane proteins and methods for the preparation and use thereof
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2014121093A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039361A1 (en) * 1997-03-03 1998-09-11 St. Jude Children's Research Hospital A lymphocyte surface receptor that binds caml, nucleic acids encoding the same and methods of use thereof
WO2000040716A2 (en) * 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
WO2000058362A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039361A1 (en) * 1997-03-03 1998-09-11 St. Jude Children's Research Hospital A lymphocyte surface receptor that binds caml, nucleic acids encoding the same and methods of use thereof
WO2000040716A2 (en) * 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
WO2000058362A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUELOW VON G-U ET AL: "NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 278, no. 5335, 3 October 1997 (1997-10-03), pages 138 - 141, XP002165404, ISSN: 0036-8075 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL

Also Published As

Publication number Publication date
EP1254227A2 (en) 2002-11-06
CA2400214A1 (en) 2001-11-15
AU3695801A (en) 2001-11-20
US20020160416A1 (en) 2002-10-31
MXPA02007574A (en) 2002-12-13
WO2001085782A2 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
WO2000047740A3 (en) Tnf-related proteins
IL160142A0 (en) Methods and compounds for the targeting of protein to exosomes
WO2004014311A3 (en) Nogo receptor antagonists
WO2004085648A3 (en) Nogo receptor binding protein
WO2005111072A3 (en) Notch-based fusion proteins and uses thereof
PL380274A1 (en) Nogo receptor antagonists
WO2000066156A8 (en) Death domain containing receptor 5
WO2003062370A3 (en) Multimeric proteins and methods of making and using same
WO2005001057A3 (en) Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof
WO2005051983A3 (en) Oligomeric complexe formation of recombinant multi subunit chimeric polypeptides
WO2000059942A3 (en) Human obesity protein binding protrein-2 homolog and uses thereof
WO2001061005A3 (en) Molecules of the pyrin domain protein family and uses thereof
EP1212340A4 (en) 29 PROTEINS ASSOCIATED WITH HUMAN CANCER
WO2002070657A8 (en) 93870, a human g-protein coupled receptor and uses therefor
WO2003095610A3 (en) Directed evolution method of generating enhanced folding polypeptide variants
AU6310100A (en) Single-chain polypeptides comprising troponin i n-terminal fragments and troponin
WO2002002771A3 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
WO2002038767A3 (en) G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2003033675A3 (en) Identification of binding partners for specific proteins
WO2001096400A3 (en) 52871, a novel human g protein coupled receptor and uses thereof
WO2001066738A3 (en) Nucleic acids, encoding human crsp1 and uses thereof
EP1251139A3 (en) Human mindin-like protein and nucleic acids encoding it
WO2003042371A3 (en) 55053, a novel human eukaryotic kinase and uses therefor
WO2001090150A3 (en) G protein-coupled receptors from human clone '26908' and uses thereof
WO2003030616A3 (en) 21132, a human g-protein coupled receptor family member and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 36958/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/007574

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 582381

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2400214

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001909174

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001909174

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001909174

Country of ref document: EP